- Clinical Trials
- April 2024
- 60 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- March 2024
- 196 Pages
Global
From €3242EUR$3,374USD£2,772GBP
€3602EUR$3,749USD£3,080GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1201EUR$1,250USD£1,027GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1441EUR$1,500USD£1,232GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Report
- January 2022
- 200 Pages
Global
From €7206EUR$7,500USD£6,161GBP
- Drug Pipelines
- October 2020
- 89 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- July 2022
- 63 Pages
Global
From €1922EUR$2,000USD£1,643GBP
- Report
- May 2022
- 35 Pages
Global
From €1922EUR$2,000USD£1,643GBP
The Angina Drug market is a subset of the Cardiovascular Drugs market, which includes drugs used to treat conditions related to the heart and circulatory system. Angina drugs are used to treat chest pain caused by reduced blood flow to the heart. These drugs can be divided into two categories: nitrates and calcium channel blockers. Nitrates are used to relax the blood vessels and increase blood flow to the heart, while calcium channel blockers are used to reduce the workload of the heart by blocking calcium from entering the cells of the heart.
Angina drugs are widely used in the treatment of cardiovascular diseases, and are often prescribed in combination with other drugs. They are available in various forms, including tablets, capsules, and injections.
Some of the major companies in the Angina Drug market include Pfizer, Merck, Novartis, Sanofi, and GlaxoSmithKline. Show Less Read more